Icosabutate

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameIcosabutate
Drug Alias Name艾可布特Icosabutato艾考布特Icosabutas562599X-5JL +[8] 
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionPeroxisome proliferator activated receptor agonistsCholesteryl ester transfer protein inhibitors
TargetsPeroxisome proliferator activated receptorCholesteryl ester transfer protein
Therapy Area/IndicationsDyslipidemiasMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBasf Se
China Registration ClassN/A

Develop Information

Active CompaniesNorthsea Therapeutics Bv
Inactive CompaniesPronova Biopharma Norge As
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsDyslipidemias

Other Information

ATC CodeN/A
Related LinksN/A